纳米颗粒传递α-酸的综合性审查
Navid Mosallaei1, Amirhossein Malaekeh-Nikouei2, Setayesh Sarraf Shirazi2
1Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
BioImpacts : BI
|November 4, 2024
概括
纳米颗粒物输送系统通过克服其低生物可用性和短半衰期来提高α-酸 (ALA) 的有效性. 这些先进的系统为各种健康状况提供了更好的稳定性和有针对性的交付.
科学领域:
- 药理学和药物输送 药理学和药物输送
- 纳米技术 纳米技术
- 生物化学 生化学
背景情况:
- 阿尔法-酸 (ALA) 具有显著的抗氧化特性,对各种健康状况具有治疗潜力.
- ALA 的临床实用性受到生物可用性差,新陈代谢快速和不良气味的限制.
- 纳米颗粒药物输送系统提供了一个有希望的策略来缓解ALA的局限性.
研究的目的:
- 对阿尔法-酸 (ALA) 的纳米颗粒输送系统进行全面审查.
- 评估各种纳米颗粒载体,以提高ALA的治疗疗效.
- 突出ALA输送方面的进步,以改善治疗结果.
主要方法:
- 关于用于ALA输送的纳米颗粒系统的文献综述.
- 载体的分类包括基于脂质的纳米粒子,纳米乳液,聚合物纳米粒子,薄膜,纳米纤维和黄金纳米粒子.
- 对优势的分析,如稳定性提高,持续释放和增强的生物可用性.
主要成果:
- 载有ALA的固体脂质纳米颗粒 (SLN) 对皮肤学应用具有前景.
- 封装ALA的体体显示出治疗脑缺血的潜力.
- 阴离子纳米乳液和酸盐涂层脂质体对眼睛和皮肤输送分别具有优势.
结论:
- 纳米颗粒系统有效地解决了ALA的生物可用性和稳定性挑战.
- 这些先进的输送策略显著提高了ALA在各种医疗领域的治疗潜力.
- 创新的纳米粒子方法为改进的基于ALA的疗法铺平了道路.
相关概念视频
Bioavailability Enhancement: Drug Solubility Enhancement
499
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
499
Bioavailability Enhancement: Drug Permeability Enhancement
352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Modified-Release Drug Delivery Systems: Bioavailability
170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160


